Trusted

Yearn Vaults Launch on Enzyme Finance as MLN Token Surges

2 mins
Updated by Kyle Baird
Join our Trading Community on Telegram

In Brief

  • Enzyme portfolio managers can access Yearn Vaults.
  • TVL on the protocol has surged over the past two weeks.
  • MLN token prices skyrocket 43% on the day.
  • promo

Decentralized finance (DeFi) protocol Yearn has teamed up with Enzyme Finance to offer greater yield opportunities for its users.

In an announcement on July 5, Enzyme Finance revealed that portfolio managers within the Enzyme app will have new opportunities to open up yield farming strategies specifically designed to their needs.

It added that users can now access a wide range of Yearn Finance strategies and manage them under one single Vault on the platform.

Enzyme Finance, formerly known as Melon Protocol before a December 2020 rebrand, allows individuals or organizations to manage their wealth and the wealth of others on a decentralized asset management platform.

State of the Vaults

Vault strategies on Yearn are specifically constructed to minimize ETH gas costs by batch processing transactions. However, there can be substantial fees to swallow for withdrawing liquidity when Ethereum is under heavy load.

At the time of press, Yearn Finance had a total value locked of $4 billion according to DeFiLlama. It has surged 660% since the beginning of 2021, largely driven by the launch of its better yielding v2 vaults in January.

Yields on its various vaults vary wildly. Vaults for the top three stablecoins, USDT, USDT, and DAI were returning just 2-3% annually. The popular yETH vault, which currently has $83 million in collateral, returned a paltry 0.65%. The top-earning vaults with over 20% in predicted annual returns were linked to Curve Finance and included yveCRV and yvBOOST.

Enzyme Finance TVL has doubled over the past week or so surging from $17 million to $53 million at the time of writing. The sudden surge in TVL can be traced back to the collaboration between Enzyme Finance and Unslashed Finance in mid-June. The protocol invested 4,000 ETH into yield strategies on Enzyme in order to “buffer up their capital base for insurance.”

MLN price pumps

Enzyme’s native token, MLN, has surged over the past 24 hours adding 43% from an intraday low of $80 to top out at $115. At the time of writing it had retreated to $105 according to CoinGecko.

In addition to the Yearn partnership, Binance listed MLN yesterday which has given the token a massive price pump. MLN was one of the best performing DeFi tokens of 2020, but it is currently down 60% from its all-time high.

Meanwhile, Yearn’s YFI cryptocurrency has ticked up 5% on the day to reach $33,900 according to CoinGecko. It too is down a chunk from its ATH, with over 63% lost since its $90,000 peak in mid-May.  

Top crypto projects in the US | November 2024
Coinrule Coinrule Explore
Coinbase Coinbase Explore
Uphold Uphold Explore
3Commas 3Commas Explore
Chain GPT Chain GPT Explore
Top crypto projects in the US | November 2024
Coinrule Coinrule Explore
Coinbase Coinbase Explore
Uphold Uphold Explore
3Commas 3Commas Explore
Chain GPT Chain GPT Explore
Top crypto projects in the US | November 2024

Disclaimer

In adherence to the Trust Project guidelines, BeInCrypto is committed to unbiased, transparent reporting. This news article aims to provide accurate, timely information. However, readers are advised to verify facts independently and consult with a professional before making any decisions based on this content. Please note that our Terms and ConditionsPrivacy Policy, and Disclaimers have been updated.

profile.jpg
Martin Young
Martin Young is a seasoned cryptocurrency journalist and editor with over 7 years of experience covering the latest news and trends in the digital asset space. He is passionate about making complex blockchain, fintech, and macroeconomics concepts understandable for mainstream audiences.   Martin has been featured in top finance, technology, and crypto publications including BeInCrypto, CoinTelegraph, NewsBTC, FX Empire, and Asia Times. His articles provide an in-depth analysis of...
READ FULL BIO
Sponsored
Sponsored